Amgen Inc.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It's Moving
AMGN Faces Analyst Warnings of -9% Downside Despite Recent Earnings Surge and Target Hikes
- Q4 revenue soared 8.6% to $9.87B, crushing $9.46B forecasts and showcasing pipeline strength countering exclusivity losses.
- FY2026 guidance of $21.60-$23.00 EPS exceeded expectations, prompting hikes like Argus to $400 (Buy) and Guggenheim to $347 (Neutral).
- Stock at all-time highs near $377 draws valuation cautions, with Deutsche Bank at $295 (Hold) implying downside as biotech peers lag.
AMGN Faces Analyst Warnings of -9% Downside Despite Recent Earnings Surge and Target Hikes
- Q4 revenue soared 8.6% to $9.87B, crushing $9.46B forecasts and showcasing pipeline strength countering exclusivity losses.
- FY2026 guidance of $21.60-$23.00 EPS exceeded expectations, prompting hikes like Argus to $400 (Buy) and Guggenheim to $347 (Neutral).
- Stock at all-time highs near $377 draws valuation cautions, with Deutsche Bank at $295 (Hold) implying downside as biotech peers lag.
When is the next earnings date for Amgen Inc. (AMGN)?
Amgen Inc. (AMGN) is scheduled to report its next earnings on Tuesday, February 3, 2026, after market close, covering the Q4 2025 quarter. The earnings conference call is set for 4:30 PM ET. This follows their prior Q3 2025 release on November 4, 2025.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Amgen's stock, believing it has potential to rise in value.
Financial Health
Amgen is showing strong profits and cash flow, indicating solid financial performance and stability.
Dividend
Amgen's dividend yield of 2.48% offers a modest return for investors seeking income. If you invested $1000, you would be paid $24.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AMGN
Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: June 17, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Compare Amgen with other stocks
Amgen vs Gilead Sciences
Amgen vs Gilead Sciences: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
